Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Silence brings the noise to Takeda with phase 2 blood cancer win

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Silence Therapeutics' phase 2 trial of divesiran, an siRNA drug for polycythemia vera, met its primary endpoint with a high response rate, positioning it as a potential competitor to Takeda and Protagonist Therapeutics' rusfertide which is nearing FDA approval.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your siRNA blood cancer drug now directly competes with a late-stage peptide therapy gaining FDA approval. Prepare for a head-to-head with Takeda’s pipeline as dosing convenience becomes a critical market edge.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

BiotechsiRNAblood-cancerclinical-trialbiotech-competitionrare-disease